biology-products/hiv-1-p24-elisa-kit--alliance--28480-tests-29-from-perkinelmer-238-1/;msg18067;topicseen

Breaking Biology Technology:Biomatrica Launches SampleWare 3.1 2 Biomatrica Launches SampleWare 3.1 3 Dendreon Appoints Hans Bishop as Chief Operating Officer 2 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3 La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 2 La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 3

[0] Biomatrica Launches SampleWare 3.1 [0] Dendreon Appoints Hans Bishop as Chief Operating Officer [0] Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors [0] La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert

Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3 FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10 BioCryst Provides Update Regarding Peramivir for Influenza 5116 1 BioCryst Provides Update Regarding Peramivir for Influenza 5116 2 BioCryst Provides Update Regarding Peramivir for Influenza 5116 3 BioCryst Provides Update Regarding Peramivir for Influenza 5116 4 BioCryst Provides Update Regarding Peramivir for Influenza 5116 5 Study explores how life experiences contribute to the biological changes of Alzheimers 10197 1 Study explores how life experiences contribute to the biological changes of Alzheimers 10197 2 Study explores how life experiences contribute to the biological changes of Alzheimers 10197 3 Doctor Visits Are Getting Short Shrift in Tight Economy 58589 1 Doctor Visits Are Getting Short Shrift in Tight Economy 58589 2

[0] FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology [0] Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection [0] Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab